These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 34964599)
41. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach. Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648 [TBL] [Abstract][Full Text] [Related]
42. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals. Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279 [TBL] [Abstract][Full Text] [Related]
43. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. Basit A; Ali T; Rehman SU J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773 [TBL] [Abstract][Full Text] [Related]
44. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. Taka E; Yilmaz SZ; Golcuk M; Kilinc C; Aktas U; Yildiz A; Gur M J Phys Chem B; 2021 Jun; 125(21):5537-5548. PubMed ID: 33979162 [TBL] [Abstract][Full Text] [Related]
45. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade. Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496 [TBL] [Abstract][Full Text] [Related]
46. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269 [TBL] [Abstract][Full Text] [Related]
47. Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor. Suleman M; Yousafi Q; Ali J; Ali SS; Hussain Z; Ali S; Waseem M; Iqbal A; Ahmad S; Khan A; Wang Y; Wei DQ Comput Biol Med; 2021 Nov; 138():104936. PubMed ID: 34655895 [TBL] [Abstract][Full Text] [Related]
48. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382 [TBL] [Abstract][Full Text] [Related]
49. Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein. Sarto C; Florez-Rueda S; Arrar M; Hackenberger CPR; Lauster D; Di Lella S Biol Chem; 2022 Apr; 403(5-6):615-624. PubMed ID: 35357791 [TBL] [Abstract][Full Text] [Related]
50. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
51. Withanone from Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804 [TBL] [Abstract][Full Text] [Related]
52. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122 [TBL] [Abstract][Full Text] [Related]
53. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor. Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655 [TBL] [Abstract][Full Text] [Related]
54. Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. Verma S; Patil VM; Gupta MK Drug Discov Today; 2022 Oct; 27(10):103312. PubMed ID: 35787481 [TBL] [Abstract][Full Text] [Related]
55. Cervids ACE2 Residues that Bind the Spike Protein can Provide Susceptibility to SARS-CoV-2. Lopes LR Ecohealth; 2023 Mar; 20(1):9-17. PubMed ID: 37106170 [TBL] [Abstract][Full Text] [Related]
56. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540 [TBL] [Abstract][Full Text] [Related]
58. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19. Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234 [TBL] [Abstract][Full Text] [Related]
59. Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence. Laurini E; Marson D; Aulic S; Fermeglia A; Pricl S ACS Nano; 2021 Apr; 15(4):6929-6948. PubMed ID: 33733740 [TBL] [Abstract][Full Text] [Related]
60. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2). Guo X; Chen Z; Xia Y; Lin W; Li H J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]